Overview
Dexketoprofen is a non-steroidal anti-inflammatory drug. It is available in the various countries in Europe, Asia and Latin America. It has analgesic, antipyretic and anti-inflammatory properties .
Indication
For short-term treatment of mild to moderate pain, including dysmenorrhoea, musculoskeletal pain and toothache .
Associated Conditions
- Ankylosing Spondylitis (AS)
- Extra-Articular Rheumatism
- Gout
- Inflammation
- Menstrual Distress (Dysmenorrhea)
- Musculoskeletal Pain
- Myalgia
- Osteoarthritis (OA)
- Pain
- Post Traumatic Pain
- Postoperative pain
- Renal Colic
- Rheumatoid Arthritis
- Spasms
- Spinal pain
- Inflammation localized
- Localized pain
- Mild to moderate pain
Research Report
Dexketoprofen: A Comprehensive Pharmacological and Clinical Review
1. Introduction to Dexketoprofen
1.1. Overview and Background
Dexketoprofen is a well-established non-steroidal anti-inflammatory drug (NSAID) recognized for its analgesic, anti-inflammatory, and antipyretic properties.[1] It holds a specific place in pharmacology as the S(+)-enantiomer of racemic ketoprofen. This stereoisomer is the pharmacologically active component, responsible for the entirety of the therapeutic effects observed with the parent compound, ketoprofen.[1] The development of dexketoprofen as a single enantiomer represents a "chiral switch" from its racemic predecessor, a strategy aimed at optimizing therapeutic action.[4]
The primary clinical application of dexketoprofen is the symptomatic treatment of mild to moderate acute pain across a variety of conditions.[1] Having first received approval in 1994 [1], dexketoprofen is currently available in numerous countries throughout Europe, Asia, and Latin America, where it serves as a common analgesic option.[1] Its utility is particularly noted in situations requiring prompt pain relief.
1.2. Chemical Properties and Formulation
Chemically, dexketoprofen is identified by the International Union of Pure and Applied Chemistry (IUPAC) name (2S)-2-(3-benzoylphenyl)propanoic acid.[1] Its molecular formula is
C16H14O3, corresponding to a molecular weight of approximately 254.28 g/mol.[1] The Chemical Abstracts Service (CAS) registry number for dexketoprofen is 22161-81-5, and it is cataloged in DrugBank under the ID DB09214.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/05/02 | N/A | Completed | Enes Celik | ||
2025/04/17 | Phase 4 | Completed | Ali Gur | ||
2025/04/08 | Phase 4 | Completed | ibrahim doğru | ||
2024/08/20 | Phase 4 | Completed | Ankara Etlik City Hospital | ||
2024/08/19 | Phase 4 | Completed | Ismail Tekin | ||
2024/05/08 | Phase 3 | Recruiting | Riadh Boukef | ||
2023/09/29 | Phase 4 | Recruiting | |||
2022/09/07 | Phase 4 | Completed | Yuzuncu Yıl University | ||
2022/03/31 | Not Applicable | Completed | |||
2022/01/04 | Not Applicable | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
KETESSE TABLET 25 mg | SIN12650P | TABLET, FILM COATED | 25mg | 3/15/2005 | |
SKUDEXA FILM-COATED TABLET 75 MG/25 MG | SIN15394P | TABLET, FILM COATED | 25 mg | 12/13/2017 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
ENANDOL 12,5 mg/g GEL | Menarini Consumer Healthcare S.A.U. | 61404 | GEL | Sin Receta | Not Commercialized |
DEXKETOPROFENO ALTAN 50 MG/2 ML SOLUCION INYECTABLE O CONCENTRADO PARA SOLUCION PARA PERFUSION EFG | Altan Pharmaceuticals Sa | 77962 | SOLUCIÓN INYECTABLE Y PARA PERFUSIÓN | Medicamento Sujeto A Prescripción Médica | Not Commercialized |
ENANGEL 12,5 mg/g GEL | Laboratorios Menarini S.A. | 61403 | GEL | Medicamento Sujeto A Prescripción Médica | Commercialized |
QUIRGEL 12,5 mg/g GEL | Retrain, S.A.U. | 61405 | GEL | Medicamento Sujeto A Prescripción Médica | Not Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.